A PD-L1xCD3 bispecific nanobody as a novel T-cell engager in treating PD-L1 overexpression melanoma

B Li, S Wang, B Shan, B Li, F Li - Molecular Immunology, 2023 - Elsevier
The development of Immune checkpoint blockade (ICB) therapy and BRAF-and MEK-
targeted therapies has reshaped the survival outcomes of the patients with advanced …

Immune cell infiltration-based prognosis in prostate cancer: a review of current knowledge

K Apusiga - Bulletin of the National Research Centre, 2023 - Springer
Background Despite the widespread use of tumor immune cell infiltrates as prognostic
biomarkers in many cancers, their use in prostate cancer remains relatively unexplored …

Stroma-specific gene expression signature identifies prostate cancer subtype with high recurrence risk

M Rasmussen, J Fredsøe, PV Salachan… - NPJ Precision …, 2024 - nature.com
Current prognostic tools cannot clearly distinguish indolent and aggressive prostate cancer
(PC). We hypothesized that analyzing individual contributions of epithelial and stromal …

A novel assessment of whole-mount Gleason grading in prostate cancer to identify candidates for radical prostatectomy: a machine learning-based multiomics study

J Ning, CP Spielvogel, D Haberl, K Trachtova… - …, 2024 - pmc.ncbi.nlm.nih.gov
Purpose: This study aims to assess whole-mount Gleason grading (GG) in prostate cancer
(PCa) accurately using a multiomics machine learning (ML) model and to compare its …

[PDF][PDF] The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives

S Ahuja, S Zaheer - Korean Journal of Clinical Oncology, 2024 - researchgate.net
Cancer immunotherapy uses the body's immune system to combat cancer, marking a
significant advancement in treatment. This review traces its evolution from the late 19th …